In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company are changing the operational and financial structure of their diabetes alliance in certain countries.
Eli Lilly said that its net income and sales sank in the third quarter after its antidepressant...
The companies announced a team-up in January but did not disclose terms. Without explaining the...
The FDA has accepted the filing of a New Drug Application for empagliflozin plus immediate-...
Eli Lilly and Company has announced plans to conclude production and pursue a sale of one of its three manufacturing plants in Puerto Rico. The manufacturing site, located in Guayama, Puerto Rico, will remain in operation until the end of 2015.
Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and Eli Lilly and Company in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis.
The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis' animal health division to U.S. pharmaceutical firm Eli Lilly. The 28-nation bloc's executive Commission said Friday the sale won't hinder competition because the merged firm will continue to face a number of strong competitors.
Eli Lilly and Company will discontinue development of tabalumab -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials.
The Food and Drug Administration has approved a new injectable diabetes drug from Eli Lilly and Co. for adults with the most common form of the disease. The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes.
AstraZeneca and Eli Lilly announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.
Lilly Says CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall SurvivalSeptember 12, 2014 8:56 am | News | Comments
Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.
European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent infringement litigation with French rival Sanofi.
Lilly said peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
Takeda Pharmaceutical has been ordered by a U.S. district court to pay $6 billion in punitive damages over a lawsuit filed by a man who claimed his bladder cancer was caused by Takeda's diabetes medicine Actos.
Eli Lilly and Co. says it will close its Elanco animal enzyme plant in Terre Haute by early 2016 as part of a consolidation push. Lilly spokesman Ed Sagebiel tells the Tribune-Star the Indianapolis-based company is consolidating all of its animal enzyme manufacturing to a site in Great Britain.
Federal regulators have approved a new treatment from U.S. drugmaker Eli Lilly and Co. and its German counterpart, Boehringer Ingelheim, for the most common form of diabetes . The Food and Drug Administration said Friday it will permit Jardiance tablets to be used by adult patients with type 2 diabetes.
Eli Lilly and Co. (LLY) on Thursday reported profit that declined by 39 percent in its second quarter, and beat analysts' expectations. The Indianapolis-based company said earnings declined to $733.5 million, or 68 cents per share, from $1.21 billion, or $1.11 per share, in the same quarter a year earlier.
Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases.
CHMP Recommends Lilly and Boehringer Ingelheim's New Insulin Glargine Product for Approval in the European UnionJune 27, 2014 8:20 am | News | Comments
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes.
The imminent patent expiration of Sanofi’s Lantus has opened the door for Eli Lilly to increase its share of the diabetes treatment market, and the US-based company has three big weapons in its pharmaceutical arsenal, says an analyst with research and consulting firm GlobalData.
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2014 of $0.49 per share on outstanding common stock.
Eli Lilly and Company today announced that the Phase III REACH trial of CYRAMZA (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant.
In one of the most ambitious attempts yet to thwart Alzheimer's disease, a major study got underway Monday to see if an experimental drug can protect healthy seniors whose brains harbor silent signs that they're at risk.
Eli Lilly and Company today announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This website, which houses data from several clinical trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
For the first time in a decade, an experimental drug has extended the life of patients with advanced lung cancer who relapsed after standard chemotherapy. But the benefit in the study was so small — six extra weeks, on average — that it is raising fresh questions about the value of some costly...
Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).
The European Commission granted marketing authorization for Jardiance (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of type 2 diabetes mellitus (T2D) to improve glycemic control in adults in Europe, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced.
Eli Lilly and Company has announced that the 2nd Circuit of the Labor Court of Paulinia in the state of Sao Paulo, Brazil, has ruled against the company's local subsidiary, Eli Lilly do Brasil, in a labor case alleging some employees were exposed to hazardous materials in a manufacturing facility operated by the company between 1977 and 2003.
The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.
- Page 1